Canaccord analyst Richard Close lowered the firm’s price target on AdaptHealth to $14 from $17 and keeps a Buy rating on the shares. The firm said they posted mixed 3Q results with a top-line beat and a bottom-line miss and its valuation reflects its execution missteps which coulds turn over the next several quarters.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on AHCO:
- AdaptHealth price target lowered to $14 from $17 at Baird
- AdaptHealth downgraded to Underperform from Neutral at BofA
- AdaptHealth narrows FY23 revenue view to $3.16B-$3.19B from $3.16B-$3.2B
- AdaptHealth reports Q3 EPS ($3.43), consensus 20c
- 3 Best Stocks to Buy Now, 10/23/2023, According to Top Analysts
